PLYMOUTH, Mich., August 27, 2020 - Ehmet Health, a medical device company, whose MammoKnifeTM is the first LINAC built specifically to treat breast cancer, announced the hiring of two significant leaders to round out their management team.
Leonard A. Farber MD, Chief Medical Officer, brings over 20+ years of clinical and entrepreneurial expertise in Radiation Oncology in both private practice and in academia, with a concentrated focus on emerging technologies in breast cancer.
His experience strengthens the product, as well as the clinical work that is putting Ehmet at the forefront of a movement that addresses the shortfalls in the treatment of breast cancer. “There have been few significant treatment advances to this extent in over 20 years,” Dr. Farber said. “The opportunity to build a new, more precise, more personal way to provide care is truly our passion.”
The need for advancement in radiation therapy has been compounded by the pandemic. “Our mission has become even more critical to address a global market and an unmet need for improved accuracy and accessibility in treating breast cancer,” said Michael Teicher, CEO, Ehmet Health. “Patients simply cannot get to hospitals for treatment the way they used to. MammoKnife™ gives patients higher quality care than previously available--and in a much more comfortable, local setting.”
Dr. Farber will also lead a host of federal grant and academic partnerships to expand the company’s research and development, potentially including other modalities and clinical applications.
Ehmet Health also announced that Kevin Murphy, MBA, has joined as Chief Financial Officer. Murphy is a seasoned healthcare executive who has completed over $100 billion dollars in M&A during more than 20 years on Wall Street and several more in finance and operational administration in both the public and private sectors. Kevin graduated from MIT and holds an MBA from Columbia.
Murphy will bring his extensive experience and relationships to create new markets within healthcare as Ehmet enters into delivering the first static and mobile breast cancer unit.
Ehmet Health is a privately held, emerging medical device company with an innovative device for providing radiation as a treatment for breast cancer. Radiation therapy remains a mainstay of treatment for breast cancer patients, yet hospitals and medical centers face significant challenges in providing all patients safe and cost-effective care. Moreover, meaningful logistical impediments keep many patients in rural areas of the country from receiving treatment. Ehmet’s MammoKnife™ was designed to address many of these challenges. The product targets a multi-billion dollar market opportunity with a rapid path to clinical use in the U.S. and Europe.
